REPL vs. CCCC, TCRX, OCGN, SLDB, LXEO, AURA, TRML, AVXL, VYGR, and EDIT
Should you be buying Replimune Group stock or one of its competitors? The main competitors of Replimune Group include C4 Therapeutics (CCCC), TScan Therapeutics (TCRX), Ocugen (OCGN), Solid Biosciences (SLDB), Lexeo Therapeutics (LXEO), Aura Biosciences (AURA), Tourmaline Bio (TRML), Anavex Life Sciences (AVXL), Voyager Therapeutics (VYGR), and Editas Medicine (EDIT). These companies are all part of the "biological products, except diagnostic" industry.
C4 Therapeutics (NASDAQ:CCCC) and Replimune Group (NASDAQ:REPL) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, community ranking, media sentiment and dividends.
78.8% of C4 Therapeutics shares are owned by institutional investors. Comparatively, 92.5% of Replimune Group shares are owned by institutional investors. 8.0% of C4 Therapeutics shares are owned by company insiders. Comparatively, 20.6% of Replimune Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Replimune Group received 127 more outperform votes than C4 Therapeutics when rated by MarketBeat users. Likewise, 61.54% of users gave Replimune Group an outperform vote while only 37.88% of users gave C4 Therapeutics an outperform vote.
In the previous week, C4 Therapeutics had 21 more articles in the media than Replimune Group. MarketBeat recorded 22 mentions for C4 Therapeutics and 1 mentions for Replimune Group. C4 Therapeutics' average media sentiment score of 1.22 beat Replimune Group's score of 0.64 indicating that Replimune Group is being referred to more favorably in the news media.
C4 Therapeutics has a beta of 3.22, suggesting that its share price is 222% more volatile than the S&P 500. Comparatively, Replimune Group has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500.
C4 Therapeutics currently has a consensus price target of $10.11, suggesting a potential upside of 65.48%. Replimune Group has a consensus price target of $37.67, suggesting a potential upside of 453.11%. Given C4 Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Replimune Group is more favorable than C4 Therapeutics.
Replimune Group has a net margin of 0.00% compared to Replimune Group's net margin of -629.24%. C4 Therapeutics' return on equity of -42.94% beat Replimune Group's return on equity.
C4 Therapeutics has higher revenue and earnings than Replimune Group. C4 Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.
Summary
Replimune Group beats C4 Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Replimune Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding REPL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Replimune Group Competitors List
Related Companies and Tools
